Simulations Plus, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Shawn O'Connor
- Full Time Employees
- 213
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 800 Park Offices Drive Research Triangle Park NC United States of America 27709
- IPO Date
- Jun 18, 1997
- CIK
- 0001023459
- Website
- simulations-plus.com
- Similar Companies
- Business
- Simulations Plus, Inc. (Nasdaq: SLP) develops and markets modeling and simulation software, along with related consulting services, for drug discovery, development research, and regulatory submissions in the pharmaceutical, biotechnology, agrochemical, cosmetics, and food industries worldwide. The company operates through Software and Services segments and offers core products including GastroPlus for physiologically based biopharmaceutics (PBPK) modeling of absorption, pharmacokinetics, and pharmacodynamics in humans and animals; ADMET Predictor, a machine learning platform for absorption, distribution, metabolism, excretion, and toxicity property prediction, data analysis, metabolism forecasting, and AI-driven drug design; DDDPlus and MembranePlus for in vitro dissolution, permeability, and hepatocyte modeling; MonolixSuite for population pharmacokinetic/pharmacodynamic (PK/PD) analyses, clinical trial simulations, and regulatory submissions; quantitative systems pharmacology/toxicology platforms such as DILIsym, RENAsym, NAFLDsym, ILDsym, IPFsym, OBESITYsym, and MITOsym for mechanistic predictions of drug-induced organ injuries and disease efficacy; MedChem Designer for molecular sketching and ADMET predictions; Thales for end-to-end QSP modeling and population optimization; Panorama for key opinion leader analytics and medical communications; and Pro-ficiency for AI-driven clinical trial simulations, performance management, adaptive learning, and insights. Simulations Plus provides clinical pharmacology consulting encompassing population PK/PD modeling, exposure-response analyses, noncompartmental analysis, pharmacometrics with Monolix and NONMEM, data programming, technical writing for regulatory filings, and early drug discovery support leveraging AI/ML and PBPK integration. Founded in 1996 and headquartered in Research Triangle Park, North Carolina, the company serves major pharmaceutical and biotechnology firms, chemical manufacturers, academic institutions, and regulatory agencies across the United States, Europe, Asia-Pacific, and other regions. In June 2024, Simulations Plus completed its largest acquisition to date with the $100 million cash purchase of Pro-ficiency Holdings, Inc. and subsidiaries from QHP Capital, doubling its total addressable market to $8 billion by integrating AI-powered clinical trial operations, training simulations, analytics, and medical communications capabilities; the deal, funded from existing cash reserves, proved accretive to fiscal 2025 earnings and expanded offerings from preclinical protocols through product commercialization. Subsequently, in August 2024, the company restructured into new business units—Adaptive Learning & Insights and Medical Communications—to optimize post-acquisition operations and enhance client engagement; in October 2025, its board adopted a revised Code of Conduct incorporating AI usage best practices while maintaining core governance principles.
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
SHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--PULM, SLP, OLN, and HUN
Simulations Plus Reports Third Quarter Fiscal 2026 Financial Results
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
Johnson Fistel Investigates Simulations Plus Following Revenue Guidance Cut and Accounting Disclosures
Shareholder Alert: Ademi LLP investigates whether Simulations Plus, Inc. is obtaining a Fair Price for Public Shareholders
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
SLP Investors Have Opportunity to Join Simulations Plus, Inc. Fraud Investigation with the Schall Law Firm
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Simulations Plus Advances Agentic Drug Development with NVIDIA BioNeMo Agent Toolkit
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel
Simulations Plus, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – SLP
Simulations Plus Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Simulations Plus, Inc. - SLP
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Simulations Plus, Inc. (NASDAQ: SLP)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Simulations Plus, Inc. (NASDAQ: SLP)
Simulations Plus (SLP) Investigation: Investors Who Suffered Losses Encouraged to Contact Johnson Fistel